3B Blackbio [3BBLACKBIO] vs Panacea Biotec [PANACEABIO] Detailed Stock Comparison
3B Blackbio
BSE
Loading...
Panacea Biotec
NSE
Loading...
TLDR: Quick Comparison Summary
Based on 19 vital metrics comparison: 3B Blackbio wins in 11 metrics, Panacea Biotec wins in 7 metrics, with 0 ties. 3B Blackbio appears stronger overall.
View Metrics Details
Vital Metrics Comparison
| Metric | 3B Blackbio | Panacea Biotec | Better |
|---|---|---|---|
| P/E Ratio (TTM) | 25.06 | 217.10 | 3B Blackbio |
| Price-to-Book Ratio | 4.79 | 2.98 | Panacea Biotec |
| Debt-to-Equity Ratio | 0.11 | 2.67 | 3B Blackbio |
| PEG Ratio | 1.91 | -1.73 | Panacea Biotec |
| EV/EBITDA | 23.83 | -182.28 | Panacea Biotec |
| Profit Margin (TTM) | 49.51% | 1.88% | 3B Blackbio |
| Operating Margin (TTM) | 51.98% | -5.74% | 3B Blackbio |
| EBITDA Margin (TTM) | 51.98% | N/A | N/A |
| Return on Equity | 17.58% | -1.01% | 3B Blackbio |
| Return on Assets (TTM) | 16.11% | -0.65% | 3B Blackbio |
| Free Cash Flow (TTM) | $424.53M | $-776.80M | 3B Blackbio |
| 1-Year Return | 2.74% | 79.88% | Panacea Biotec |
| Price-to-Sales Ratio (TTM) | 12.42 | 4.10 | Panacea Biotec |
| Enterprise Value | $12.16B | $24.12B | Panacea Biotec |
| EV/Revenue Ratio | 12.25 | 3.95 | Panacea Biotec |
| Gross Profit Margin (TTM) | 75.00% | 53.68% | 3B Blackbio |
| Revenue per Share (TTM) | $116 | $100 | 3B Blackbio |
| Earnings per Share (Diluted) | $57.31 | $1.88 | 3B Blackbio |
| Beta (Stock Volatility) | 0.28 | 0.34 | 3B Blackbio |
Performance
Key Stats
Valuation
Financials
Short Interest
Dividends
3B Blackbio vs Panacea Biotec Stock Performance Analysis
Loading Price Chart...
Performance Comparison
Short-term Returns
| Stock | 1D | 1W | 1M | 3M | 6M | YTD |
|---|---|---|---|---|---|---|
| 3B Blackbio | 1.64% | -11.51% | -1.70% | -25.19% | -20.50% | -27.08% |
| Panacea Biotec | -2.16% | -1.20% | -3.47% | -25.64% | 25.69% | -8.21% |
Long-term Returns
| Stock | 1Y | 3Y | 5Y | 10Y | 15Y | 20Y |
|---|---|---|---|---|---|---|
| 3B Blackbio | 2.74% | 80.63% | 80.63% | 80.63% | 80.63% | 80.63% |
| Panacea Biotec | 79.88% | 188.45% | 155.14% | 208.41% | 111.26% | 51.88% |
Performance & Financial Health Analysis: 3B Blackbio vs Panacea Biotec
| Metric | 3BBLACKBIO | PANACEABIO |
|---|---|---|
| Market Information | ||
| Market Cap | ₹12.33B | ₹25.00B |
| Market Cap Category | Small cap | Small cap |
| 10 Day Avg. Volume | 11,965 | 235,549 |
| 90 Day Avg. Volume | 8,132 | 190,641 |
| Last Close | ₹1,436.75 | ₹394.70 |
| 52 Week Range | ₹1,253.80 - ₹2,350.00 | ₹200.05 - ₹581.90 |
| % from 52W High | -38.86% | -32.17% |
| All-Time High | ₹2,350.00 (Dec 09, 2024) | ₹581.90 (Apr 28, 2025) |
| % from All-Time High | -38.86% | -32.17% |
| Growth Metrics | ||
| Quarterly Revenue Growth | 0.14% | 0.44% |
| Quarterly Earnings Growth | 0.13% | 0.44% |
| Financial Health | ||
| Profit Margin (TTM) | 0.50% | 0.02% |
| Operating Margin (TTM) | 0.52% | -0.06% |
| Return on Equity (TTM) | 0.18% | -0.01% |
| Debt to Equity (MRQ) | 0.11 | 2.67 |
| Cash & Liquidity | ||
| Book Value per Share (MRQ) | ₹299.81 | ₹136.92 |
| Cash per Share (MRQ) | ₹14.62 | ₹17.95 |
| Operating Cash Flow (TTM) | ₹619.97M | ₹-1,547,900,000 |
| Levered Free Cash Flow (TTM) | ₹476.52M | ₹-83,700,000 |
| Dividends | ||
| Last 12-Month Dividend Yield | N/A | N/A |
| Last 12-Month Dividend | N/A | ₹0.00 |
Valuation & Enterprise Metrics Analysis: 3B Blackbio vs Panacea Biotec
| Metric | 3BBLACKBIO | PANACEABIO |
|---|---|---|
| Price Ratios | ||
| P/E Ratio (TTM) | 25.06 | 217.10 |
| Forward P/E | N/A | N/A |
| PEG Ratio | 1.91 | -1.73 |
| Price to Sales (TTM) | 12.42 | 4.10 |
| Price to Book (MRQ) | 4.79 | 2.98 |
| Market Capitalization | ||
| Market Capitalization | ₹12.33B | ₹25.00B |
| Enterprise Value | ₹12.16B | ₹24.12B |
| Enterprise Value Metrics | ||
| Enterprise to Revenue | 12.25 | 3.95 |
| Enterprise to EBITDA | 23.83 | -182.28 |
| Risk & Other Metrics | ||
| Beta | 0.28 | 0.34 |
| Book Value per Share (MRQ) | ₹299.81 | ₹136.92 |
Financial Statements Comparison: 3B Blackbio vs Panacea Biotec
Financial Metrics
Loading Financial Charts...
Revenue
EBITDA
Operating Margin
Free Cash Flow
Long Term Debt
Profit Margin
Current Ratio
Operating Cash Flow
Income Statement (MRQ)
| Metric (MRQ) | 3BBLACKBIO | PANACEABIO |
|---|---|---|
| Revenue/Sales | ₹222.35M | ₹1.33B |
| Cost of Goods Sold | ₹55.60M | ₹520.80M |
| Gross Profit | ₹166.75M | ₹804.50M |
| Research & Development | N/A | N/A |
| Operating Income (EBIT) | ₹115.57M | ₹-353.00M |
| EBITDA | ₹161.51M | ₹-182.90M |
| Pre-Tax Income | ₹158.64M | ₹-400,000 |
| Income Tax | ₹32.19M | ₹19.50M |
| Net Income (Profit) | ₹126.45M | ₹-19.90M |
Balance Sheet & Liquidity Metrics (MRQ)
| Metric (MRQ) | 3BBLACKBIO | PANACEABIO |
|---|---|---|
| Cash & Equivalents | ₹124.73M | ₹821.30M |
| Total Current Assets | ₹1.32B | ₹5.45B |
| Total Current Liabilities | ₹185.88M | ₹3.67B |
| Long-Term Debt | ₹3.07M | ₹222.10M |
| Total Shareholders Equity | ₹2.71B | ₹8.31B |
| Retained Earnings | N/A | N/A |
| Property, Plant & Equipment | ₹72.19M | ₹5.43B |
Cash Flow Statement Comparison (MRQ)
| Metric (MRQ) | 3BBLACKBIO | PANACEABIO |
|---|---|---|
| Operating Cash Flow | N/A | N/A |
| Capital Expenditures | N/A | N/A |
| Free Cash Flow | N/A | N/A |
| Debt Repayment | N/A | N/A |
| Common Stock Repurchase | N/A | N/A |
Short Interest & Institutional Ownership Analysis
| Metric | 3BBLACKBIO | PANACEABIO |
|---|---|---|
| Shares Short | N/A | N/A |
| Short Ratio | N/A | N/A |
| Short % of Float | N/A | N/A |
| Average Daily Volume (10 Day) | 11,965 | 235,549 |
| Average Daily Volume (90 Day) | 8,132 | 190,641 |
| Shares Outstanding | 8.58M | 61.25M |
| Float Shares | 2.62M | 15.44M |
| % Held by Insiders | 0.65% | 0.73% |
| % Held by Institutions | 0.02% | 0.00% |
Dividend Analysis & Yield Comparison: 3B Blackbio vs Panacea Biotec
| Metric | 3BBLACKBIO | PANACEABIO |
|---|---|---|
| Last 12-Month Dividend | N/A | ₹0.00 |
| Last 12-Month Dividend Yield | N/A | N/A |
| 3-Year Avg Annual Dividend | N/A | ₹0.00 |
| 3-Year Avg Dividend Yield | N/A | N/A |
| 3-Year Total Dividends | N/A | ₹0.00 |
| Ex-Dividend Date | N/A | N/A |